CARsgen Pharma Holdings Limited – Trademark Portfolio
Entity Type: 99
CARsgen Pharma Holdings Limited holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include CYCLOCAR, THANK-UCAR, and CARCELERATE. The owner is based in WAN CHAI.
FLAT/RM A, 12/F, KIU FU COMMERCIAL BLDG
300 LOCKHART ROAD
WAN CHAI , HK
Showing of trademarks Trademarks
Trademark Classifications
CARsgen Pharma Holdings Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does CARsgen Pharma Holdings Limited have?
CARsgen Pharma Holdings Limited has 6 U.S. trademarks filed with the USPTO. Of these, 6 registered.
What trademark classes does CARsgen Pharma Holdings Limited file in?
CARsgen Pharma Holdings Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are CARsgen Pharma Holdings Limited's most well-known trademarks?
CARsgen Pharma Holdings Limited's registered trademark portfolio includes well-known marks such as CYCLOCAR, THANK-UCAR, and CARCELERATE. These are among 6 currently registered trademarks in the portfolio.
What is CARsgen Pharma Holdings Limited's trademark registration success rate?
CARsgen Pharma Holdings Limited has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.